Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Change in Accured Expenses: 2019-2024

Historic Change in Accured Expenses for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $11.8 million.

  • Nurix Therapeutics' Change in Accured Expenses rose 4.94% to $6.3 million in Q3 2025 from the same period last year, while for Aug 2025 it was $15.3 million, marking a year-over-year increase of 160.64%. This contributed to the annual value of $11.8 million for FY2024, which is 278.35% up from last year.
  • Per Nurix Therapeutics' latest filing, its Change in Accured Expenses stood at $11.8 million for FY2024, which was up 278.35% from $3.1 million recorded in FY2023.
  • Nurix Therapeutics' 5-year Change in Accured Expenses high stood at $11.8 million for FY2024, and its period low was $2.3 million during FY2020.
  • Moreover, its 3-year median value for Change in Accured Expenses was $7.5 million (2022), whereas its average is $7.5 million.
  • Per our database at Business Quant, Nurix Therapeutics' Change in Accured Expenses plummeted by 58.28% in 2023 and then skyrocketed by 278.35% in 2024.
  • Nurix Therapeutics' Change in Accured Expenses (Yearly) stood at $2.3 million in 2020, then spiked by 172.48% to $6.2 million in 2021, then grew by 20.38% to $7.5 million in 2022, then tumbled by 58.28% to $3.1 million in 2023, then soared by 278.35% to $11.8 million in 2024.